secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266979
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics Q3 net loss $108M; DMD topline data expected Dec 2025; DM1 enrollment delayed to early Q2 2026
--------------------------------------------------------------------------------

- Net loss $108.0M ($0.76/share) vs $97.1M ($0.96/share) in Q3 2024; R&D $97.2M, G&A $16.7M.
- Cash $791.9M; reaffirms runway into Q3 2027 covering first commercial launch and BLA submissions.
- Topline data from DELIVER REC (z-rostudirsen in DMD) on track for Dec 2025; BLA submission Q2 2026, launch Q1 2027.
- ACHIEVE REC enrollment (z-basivarsen in DM1) now expected early Q2 2026 (shift from Q4 2025) due to US site activation.
- FDA granted Breakthrough Therapy Designation for z-rostudirsen in Aug 2025; one-year DM1 data presented at WMS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525266979/0001193125-25-266979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312525266979/dyn-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer